| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3872492 | The Journal of Urology | 2010 | 6 Pages |
Abstract
Preoperative treatment with sunitinib is safe. Sunitinib decreased the size of primary renal cell carcinoma in 17 of 20 patients. Future trials can be considered to evaluate neoadjuvant sunitinib to maximize nephron sparing and decrease the recurrence of high risk, localized renal cell carcinoma.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
Nicholas J. Hellenthal, Willie Underwood, Remedios Penetrante, Alan Litwin, Shaozeng Zhang, Gregory E. Wilding, Bin T. Teh, Hyung L. Kim,